# AbbVie Inc. (ABBV) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from AbbVie Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/ABBV/mda/fy2025/): filed 2026-02-20; accession 0001551152-26-000008 (https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/ABBV/mda/fy2024/): filed 2025-02-14; accession 0001551152-25-000020 (https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm)
- [FY 2023 MD&A](/company/ABBV/mda/fy2023/): filed 2024-02-20; accession 0001551152-24-000011 (https://www.sec.gov/Archives/edgar/data/1551152/000155115224000011/abbv-20231231.htm)
- [FY 2022 MD&A](/company/ABBV/mda/fy2022/): filed 2023-02-17; accession 0001551152-23-000011 (https://www.sec.gov/Archives/edgar/data/1551152/000155115223000011/abbv-20221231.htm)
- [FY 2021 MD&A](/company/ABBV/mda/fy2021/): filed 2022-02-18; accession 0001551152-22-000007 (https://www.sec.gov/Archives/edgar/data/1551152/000155115222000007/abbv-20211231.htm)

Back to /company/ABBV/